These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32134405)

  • 1. [Pharmacological strategy pre- and post-percutaneous coronary intervention in patients with acute coronary syndrome on oral anticoagulation therapy].
    Franchina AG; Capodanno D
    G Ital Cardiol (Rome); 2020 Feb; 21(2 Suppl 1):26S-33S. PubMed ID: 32134405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis.
    Haller PM; Sulzgruber P; Kaufmann C; Geelhoed B; Tamargo J; Wassmann S; Schnabel RB; Westermann D; Huber K; Niessner A; Gremmel T
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):226-236. PubMed ID: 31198930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Management of antithrombotic therapy in patients with bleeding after percutaneous coronary intervention].
    Capranzano P; Francaviglia B; Capodanno D; Tamburino C
    G Ital Cardiol (Rome); 2020 Feb; 21(2 Suppl 1):34S-41S. PubMed ID: 32134406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients.
    Galli M; Andreotti F; Porto I; Crea F
    Europace; 2020 Apr; 22(4):538-546. PubMed ID: 31942971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
    Gargiulo G; Cannon CP; Gibson CM; Goette A; Lopes RD; Oldgren J; Korjian S; Windecker S; Esposito G; Vranckx P; Valgimigli M
    Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f50-f60. PubMed ID: 33119069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic therapy in coronary artery disease patients with atrial fibrillation.
    Wei L; Su E; Liu W; Xing W; Liu X; Zhang Y; Wang S; Cheng Q; Qi D; Gao C
    BMC Cardiovasc Disord; 2020 Jul; 20(1):323. PubMed ID: 32631244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Sullivan AE; Nanna MG; Rao SV; Cantrell S; Gibson CM; Verheugt FWA; Peterson ED; Lopes RD; Alexander JH; Granger CB; Yee MK; Kong DF
    Catheter Cardiovasc Interv; 2020 Aug; 96(2):E102-E109. PubMed ID: 31713326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting.
    Lacoste JL; Hansen CL
    Am J Health Syst Pharm; 2019 Sep; 76(18):1395-1402. PubMed ID: 31505555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.
    Lopes RD; Vora AN; Liaw D; Granger CB; Darius H; Goodman SG; Mehran R; Windecker S; Alexander JH
    Am Heart J; 2018 Jun; 200():17-23. PubMed ID: 29898844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Short dual antiplatelet therapy: how, when and why].
    Ditali V; Carrozzi C; Leonardi S
    G Ital Cardiol (Rome); 2020 Feb; 21(2 Suppl 1):14S-25S. PubMed ID: 32134404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy?
    Fluschnik N; Becher PM; Schnabel R; Blankenberg S; Westermann D
    Herz; 2018 Feb; 43(1):20-25. PubMed ID: 29188358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.
    Angiolillo DJ; Goodman SG; Bhatt DL; Eikelboom JW; Price MJ; Moliterno DJ; Cannon CP; Tanguay JF; Granger CB; Mauri L; Holmes DR; Gibson CM; Faxon DP
    Circulation; 2018 Jul; 138(5):527-536. PubMed ID: 30571525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic treatment in atrial fibrillation patients undergoing PCI: Is dual therapy the winner?
    Mantis C; Alexopoulos D
    Thromb Res; 2019 Apr; 176():133-139. PubMed ID: 30826397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Versus Triple Antithrombotic Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation: An Updated Meta-Analysis.
    Goel S; Pasam RT; Sharma A; Gidwani U
    Cardiovasc Revasc Med; 2020 Feb; 21(2):239-241. PubMed ID: 31718958
    [No Abstract]   [Full Text] [Related]  

  • 16. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and / or undergoing percutaneous coronary intervention.
    Mihajlovic M; Marinkovic M; Kozieł M; Mujovic N; Lip GYH; Potpara TS
    Kardiol Pol; 2020 Jun; 78(6):512-519. PubMed ID: 32543800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Saito Y; Kobayashi Y
    J Cardiol; 2019 Jan; 73(1):1-6. PubMed ID: 30293674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting.
    Reed GW; Cannon CP
    Clin Cardiol; 2013 Oct; 36(10):585-94. PubMed ID: 23873635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double or triple antithrombotic therapy after coronary stenting and atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials.
    Andò G; Costa F
    Int J Cardiol; 2020 Mar; 302():95-102. PubMed ID: 31924397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of single vs dual antiplatelet therapy in patients on anticoagulation undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
    Atti V; Turagam MK; Garg J; Velagapudi P; Patel NJ; Basir MB; Mujer MT; Rayamajhi S; Abela GS; Koerber S; Gopinnathanair R; Lakkireddy D
    J Cardiovasc Electrophysiol; 2019 Nov; 30(11):2460-2472. PubMed ID: 31432607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.